| __timestamp | Halozyme Therapeutics, Inc. | ImmunityBio, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 79696000 | 1595000 |
| Thursday, January 1, 2015 | 93236000 | 11434000 |
| Friday, January 1, 2016 | 150842000 | 26546000 |
| Sunday, January 1, 2017 | 150643000 | 39778000 |
| Monday, January 1, 2018 | 150252000 | 53418000 |
| Tuesday, January 1, 2019 | 140804000 | 111997000 |
| Wednesday, January 1, 2020 | 34236000 | 139507000 |
| Friday, January 1, 2021 | 35672000 | 195958000 |
| Saturday, January 1, 2022 | 66607000 | 248149000 |
| Sunday, January 1, 2023 | 76363000 | 232366000 |
| Monday, January 1, 2024 | 79048000 |
Cracking the code
In the ever-evolving world of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Halozyme Therapeutics, Inc. and ImmunityBio, Inc. have demonstrated contrasting approaches to R&D investment. From 2014 to 2023, Halozyme's R&D expenses fluctuated, peaking in 2016 with a 50% increase from 2014, before experiencing a significant dip in 2020. In contrast, ImmunityBio's R&D spending skyrocketed, growing by over 14,500% from 2014 to 2022, reflecting a robust commitment to advancing their pipeline. This divergence highlights the strategic differences in how these companies allocate resources to fuel innovation. As the biotech landscape continues to shift, understanding these spending patterns offers valuable insights into the future trajectories of these industry players.
Comparing Innovation Spending: Johnson & Johnson and ImmunityBio, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Zoetis Inc. and Halozyme Therapeutics, Inc.
Research and Development: Comparing Key Metrics for Intra-Cellular Therapies, Inc. and Halozyme Therapeutics, Inc.
R&D Spending Showdown: Insmed Incorporated vs ImmunityBio, Inc.
Research and Development: Comparing Key Metrics for Halozyme Therapeutics, Inc. and Pharming Group N.V.
Halozyme Therapeutics, Inc. vs Xenon Pharmaceuticals Inc.: Strategic Focus on R&D Spending
R&D Spending Showdown: Halozyme Therapeutics, Inc. vs Perrigo Company plc
R&D Insights: How Halozyme Therapeutics, Inc. and Mesoblast Limited Allocate Funds
R&D Insights: How Lantheus Holdings, Inc. and ImmunityBio, Inc. Allocate Funds
Research and Development: Comparing Key Metrics for Amneal Pharmaceuticals, Inc. and ImmunityBio, Inc.
Perrigo Company plc or ImmunityBio, Inc.: Who Invests More in Innovation?
Who Prioritizes Innovation? R&D Spending Compared for ImmunityBio, Inc. and Celldex Therapeutics, Inc.